This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Purine nucleoside phosphorylase [PNP] deficiency퓨린뉴클레오사이드인산화효소결핍

ICD-10: D81.5 | Synonyms: PNP deficiency, Purine nucleoside phosphorylase deficiency

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First discovery and description

PNP deficiency became known when Giblett et al. in 1975 first reported the absence of erythrocyte PNP enzyme activity in two pediatric patients with T-cell immunodeficiency. This was shortly after the discovery of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency at around the same time, and with this the association between purine metabolic enzyme deficiencies and immunodeficiency began to attract attention.

Comparative studies with ADA deficiency

It was gradually established that, whereas ADA deficiency causes loss of function of both T cells and B cells, PNP deficiency mainly causes loss of T-cell function with relative preservation of B-cell function. Cohen et al. in 1977 proposed that deoxyguanosine (dGuo) accumulates in PNP deficiency patients and exerts selectively toxic effects on T lymphocytes.

Molecular genetic characterization

Williams, Bzik, et al. in 1987 cloned the human PNP gene and confirmed its location on chromosome 14q13.1. Since then, more than 30 pathogenic variants have been reported internationally, and it is an extremely rare primary immunodeficiency with more than 70 patients reported worldwide to date.

Situation in Korea

In Korea, PNP deficiency is reported very rarely, and a small number of cases have been registered through the Korean society for immunodeficiency and rare disease registries. With advances in diagnostic technology and expansion of newborn screening, the number of diagnosed cases is expected to increase in the future.

2. Causes

Role of the PNP enzyme

Purine nucleoside phosphorylase (PNP) is an enzyme in the purine salvage pathway that converts inosine, guanosine, deoxyinosine, and deoxyguanosine to hypoxanthine and guanine, respectively. When this enzyme is deficient, its substrate deoxyguanosine accumulates excessively and is toxic to immune cells.

Mechanism of toxicity

Accumulated deoxyguanosine is phosphorylated to deoxyguanosine triphosphate (dGTP) within T lymphocytes, and imbalance of the intracellular dGTP pool leads to impaired DNA synthesis and repair, mitochondrial dysfunction, and induction of apoptosis. T cells are more vulnerable to this pathway than B cells, resulting in selective T-cell immunodeficiency.

PNP gene variants

Various point mutations, deletions, and splicing variants of the PNP gene (14q13.1) have been reported as causes. Common variants include p.Arg234Pro and p.Gly156Ala, but different variants are found in different ethnic groups.

3. Genetics

Mode of inheritance

PNP deficiency is inherited in an autosomal recessive manner. Both parents are carriers, each with one pathogenic variant, and the probability of disease in a child is 25%.

Gene location and structure

The PNP gene is located on the long arm of chromosome 14 at 13.1 (14q13.1) and consists of 6 exons over a genomic region of about 8.3 kb. The gene product functions as a homotrimer with a molecular weight of about 32 kDa.

Genotype-phenotype correlation

Complete deficiency with no residual enzyme activity (null mutation) causes severe immunodeficiency from early life. With some missense variants, residual activity remains, so the age of onset may be somewhat later or clinical symptoms milder. Whether neurological symptoms (spastic paraplegia, cognitive impairment) appear does not necessarily correspond to genotype.

Carrier detection

Carrier status can be determined in parents and siblings by measurement of PNP enzyme activity and molecular genetic testing. Carriers show about 50% enzyme activity but have no clinical symptoms.

4. General epidemiology

Worldwide prevalence

PNP deficiency is an extremely rare disease even among primary immunodeficiencies, with about 70–100 patients reported in the literature worldwide. The exact prevalence is unknown, but the estimated incidence is less than 1 per million births.

Sex distribution and age of onset

There is no sex difference. Symptoms usually appear between 6 months and 2 years of age, and the mean age at first presentation is reported as 1.5 years. Some patients are diagnosed later, and neurological symptoms sometimes appear before immune symptoms.

Status in Korea

Several patients with PNP deficiency are registered with the Korean Academy of Pediatric Allergy and Respiratory Disease and the national rare disease registry system, but accurate statistics are limited. Introduction of newborn screening programs for primary immunodeficiency (T-cell receptor excision circle testing, TREC assay) is being discussed in Korea, and early detection is expected to become possible in the future.

Geographic distribution

It is not concentrated in any particular ethnic group or region and has been reported in diverse ethnic groups. The frequency may be relatively higher in populations where consanguineous marriage is common.

5. Pathophysiology

Impairment of the purine metabolic pathway

Normally, PNP converts purine nucleosides (guanosine, inosine, etc.) to purine bases (guanine, hypoxanthine) for recycling. When PNP is deficient, deoxyguanosine accumulates in cells, causing an imbalance in the nucleotide pools of nucleic acids.

dGTP pool imbalance and T-cell toxicity

Compared with B lymphocytes, T lymphocytes have lower 5'-nucleotidase activity and higher deoxyguanosine kinase (dGK) activity, so they preferentially convert deoxyguanosine to dGTP. Accumulated dGTP inhibits ribonucleotide reductase, impairing DNA synthesis overall, and excess dGTP within mitochondria induces impaired mitochondrial DNA replication and apoptosis.

Mechanism of nervous system toxicity

Reduced production of uric acid lowers serum uric acid levels, resulting in hypouricemia. In the nervous system as well, accumulation of purine nucleosides is presumed to be involved in neuronal dysfunction and abnormal myelination, but the exact mechanism has not yet been fully elucidated.

Pattern of immunodeficiency

Progressive decline of T lymphocytes is the main pathogenesis; B lymphocyte numbers are initially normal, but antibody production declines secondarily owing to lack of T-cell help. Autoimmune phenomena (autoimmune hemolytic anemia, thrombocytopenia, etc.) may appear in association with T-cell dysregulation.

6. Symptoms

Recurrent infections

The main clinical symptoms of PNP deficiency are recurrent and severe infections. Bacterial infections (pneumonia, otitis media, sepsis), viral infections (especially varicella-zoster, CMV, EBV, adenovirus), fungal infections (Candida, Aspergillus), and opportunistic infections (Pneumocystis pneumonia, Pneumocystis jirovecii) occur frequently. Disseminated infection can occur after vaccination with live vaccines (BCG, MMR, varicella).

Neurologic symptoms

A distinctive feature of PNP deficiency is that neurological symptoms accompany it. Spastic paraplegia, developmental delay, cognitive impairment, behavioral disorders, ataxia, and seizures appear in about 50–70% of patients. Neurological symptoms can persist even after the immunodeficiency is corrected, so an independent pathogenic mechanism is presumed.

Autoimmune complications

Autoimmune hemolytic anemia, immune thrombocytopenia, autoimmune thyroid disease, and systemic lupus erythematosus (SLE)–like symptoms have been reported. These are understood as the result of impaired T-cell regulatory function.

7. Signs

Physical examination findings

On physical examination, failure to thrive, lymph node atrophy, and absent or atrophic tonsils may be observed. Signs of chronic respiratory infection and otitis media are seen as traces of recurrent infections. On neurological examination, upper motor neuron signs such as increased muscle tone, hyperreflexia, and a positive Babinski sign may be identified.

Laboratory findings

Lymphopenia, particularly a marked decrease in CD3+, CD4+, and CD8+ T cells, is characteristic. CD19+ B-cell numbers may be normal or increased initially, but antibody production capacity is reduced. Serum immunoglobulins (IgG, IgA, IgM) are decreased. Serum uric acid is markedly low (hypouricemia). Inosine, guanosine, deoxyinosine, and deoxyguanosine are increased in urine and serum. Erythrocyte PNP enzyme activity is markedly reduced or absent.

Imaging findings

On chest CT, an absent or atrophic thymus may be observed. On brain MRI, white matter degeneration and brain atrophy are found in patients with neurological symptoms.

8. Screening

TREC-based newborn screening

The T-cell receptor excision circle (TREC) test is a method of indirectly assessing T-cell numbers in neonatal dried blood spots (DBS) and is used for early detection of T-cell immunodeficiency diseases including PNP deficiency. The United States and some European countries include the TREC test in their newborn screening panels, and its introduction is also being reviewed in Korea.

Immunological screening

When there is a family history (primary immunodeficiency, infant death, etc.), lymphocyte subset analysis (T, B, NK cells) and immunoglobulin quantification are performed as screening tests in the neonatal period or early infancy.

Enzyme activity screening

Hypouricemia (serum uric acid < 2 mg/dL) is a finding strongly suggestive of PNP deficiency, and if this finding is present in a child with immunodeficiency, PNP enzyme activity should be measured immediately.

Screening status in Korea

In Korea, TREC-based newborn screening has not yet been standardized, and most cases are discovered through immunological testing at secondary care institutions after recurrent infections or symptoms of immunodeficiency appear.

9. Diagnosis

Measurement of PNP enzyme activity

Measurement of PNP enzyme activity in erythrocyte lysates is the first-priority diagnostic method. In patients, enzyme activity is reduced to less than 1–2% of normal, while carriers retain about 50% activity. Recent transfusion must always be considered when interpreting results.

Urine and serum metabolite analysis

Elevated concentrations of inosine, guanosine, deoxyinosine, deoxyguanosine, and deoxyguanosine triphosphate (dGTP) are found in urine and serum. Urinary purine metabolite profiling is useful for differentiation from ADA deficiency.

Molecular genetic testing

Pathogenic variants are confirmed by sequencing of the PNP gene or NGS panel testing. Identification of two pathogenic variants together with the enzyme activity result is the criterion for confirmation.

Immunologic evaluation

On lymphocyte subset analysis, decreased T cells (CD3+, CD4+, CD8+), normal or relatively increased B-cell (CD19+) numbers, and reduced serum immunoglobulins are characteristic. On lymphocyte proliferation assays (PHA, ConA, antigen stimulation), T-cell proliferative responses are reduced.

Prenatal diagnosis

When there is a family history, PNP gene variants can be identified in fetal DNA, or enzyme activity measured in amniotic fluid cells, via chorionic villus sampling or amniocentesis.

10. Treatment

Hematopoietic stem cell transplantation (HSCT)

The only curative treatment for PNP deficiency is allogeneic hematopoietic stem cell transplantation (allogeneic HSCT). Transplantation is performed from an HLA-matched sibling donor or an unrelated donor, and immune function is restored when transplantation succeeds. Performing transplantation as early as possible (as soon as possible after diagnosis, before infections occur) is important for prognosis. However, neurological symptoms often show limited improvement even after transplantation.

Immunoglobulin replacement therapy

Before transplantation or in patients ineligible for transplantation, intravenous immunoglobulin (IVIG) is given to reduce the risk of infection. IVIG is not a curative treatment for the immunodeficiency and is used as adjunctive therapy.

Prophylactic anti-infective therapy

Trimethoprim-sulfamethoxazole (TMP-SMX) for prevention of Pneumocystis pneumonia, antifungals for prevention of fungal infections, and antivirals (acyclovir, ganciclovir) for prevention of viral infections are used. Live vaccines are contraindicated, and all blood products are given after irradiation.

Management of neurological symptoms

For neurological symptoms, symptomatic treatment such as physical therapy, occupational therapy, speech therapy, and anticonvulsants is provided.

Enzyme replacement therapy and gene therapy

PEG-conjugated PNP enzyme replacement therapy (pegylated-PNP), similar to that in ADA deficiency, is being studied but has not yet reached clinical approval. Gene correction therapy (lentiviral vector, CRISPR/Cas9-based) is being studied at the preclinical stage.

11. Prognosis

Prognosis without treatment

Without treatment, PNP deficiency often leads to death in childhood from recurrent severe infections. A considerable number of reported patients died before diagnosis or before transplantation.

Prognosis after HSCT

With early transplantation (before infectious complications occur), the transplant success rate is high and recovery of immune function is possible. However, neurological symptoms often remain partially or persistently even after transplantation, affecting quality of life.

Neurological prognosis

If neurological damage has already progressed before transplantation, spastic paralysis, cognitive impairment, and developmental delay may persist after transplantation. Therefore, early diagnosis and prompt transplantation are also important for neurological prognosis.

Long-term follow-up

In patients with successful transplantation, immune function, neurological status, growth, and development are followed long term. Autoimmune complications are also continuously monitored.

12. Prevention

Genetic counseling

Parents and siblings of patients with PNP deficiency should have their carrier status determined by molecular genetic testing and receive adequate genetic counseling about the risk when planning future births.

Prenatal diagnosis and preimplantation genetic testing

When both parents carry pathogenic variants, prenatal diagnosis is possible in the next pregnancy by chorionic villus sampling or amniocentesis. With in vitro fertilization, implantation of affected embryos can be prevented through preimplantation genetic testing (PGT-M).

Contraindication of live vaccines

When PNP deficiency is diagnosed, live vaccines such as BCG, MMR, varicella, and rotavirus are absolutely contraindicated. If already given, the possibility of disseminated infection must be evaluated.

Infection prevention and early treatment

After confirmation and until transplantation, prophylactic antibiotics, antifungals, antivirals, and IVIG treatment are given together to prevent infectious complications. When symptoms of suspected infection occur, treatment is started promptly.

Expansion of newborn screening programs

The long-term prevention strategy is to pursue improved prognosis by introducing TREC-based newborn screening, enabling early diagnosis and transplantation before symptoms appear.

13. References

  1. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1(7914):1010-1013.
  2. Cohen A, Gudas LJ, Ammann AJ, et al. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest. 1978;61(5):1405-1409.
  3. Williams SR, Bzik DJ, Bhatt S, et al. Cloning and nucleotide sequence of human purine nucleoside phosphorylase. Proc Natl Acad Sci USA. 1987;84(3):695-699.
  4. Simmonds HA, Fairbanks LD, Morris GS, et al. Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. Arch Dis Child. 1987;62(4):385-391.
  5. Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3(1):45-81.
  6. Grunebaum E, Cohen A, Roifman CM. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol. 2013;13(6):630-638.
  7. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol. 2007;123(2):139-147.
  8. Oso OO, Seye A, Nourse CB. Purine nucleoside phosphorylase deficiency presenting as neurological manifestations before immunodeficiency: a case report. J Med Case Rep. 2021;15(1):350.
  9. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2014;5:162.
  10. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
  11. Gaspar HB, Qasim W, Davies EG, et al. How I treat ADA deficiency. Blood. 2013;122(17):2974-2984.
  12. Lougaris V, Soresina A, Gazzurelli L, et al. Long-term follow-up of 168 patients with X-linked agammaglobulinemia: the Italian experience. J Allergy Clin Immunol. 2014;134(5):1210-1213.